Overview

Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
A randomized placebo-controlled study to evaluate the efficacy of PRX-03140 monotherapy in subjects with Alzheimer's disease. The study consists of a 3-month double-blind treatment period and an optional 3-month extension period.
Phase:
Phase 2
Details
Lead Sponsor:
Epix Pharmaceuticals, Inc.
Treatments:
Donepezil